Health
EyePoint LUGANO misses endpoint despite 42% reduction
EyePoint (NASDAQ:EYPT) said DURAVYU 2.7mg missed LUGANO’s primary BCVA endpoint against 2mg aflibercept in the full Phase 3 dataset.
United States Health
Health
InspireMD Q2 revenue holds at $1.8 million
InspireMD (NASDAQ:NSPR) reported Q2 2026 revenue of $1.77 million, down 0.4% year-over-year, while its net loss widened to $14.3 million.
Health
Lifeward Q2 revenue skyrockets 16% to $6.6 million
Lifeward (NASDAQ:LFWD) reported Q2 2026 revenue of $6.62 million, up 16% year-over-year, while adjusted loss was $1.46 per share.
Health
SINOVAC first-half sales rise to $147.1 million
Sinovac Biotech (NASDAQ:SVA) reported first-half 2026 sales of $147.1 million, up from $130.3 million, while net loss attributable to common shareholders widened to $60.2 million.
Health
AstraZeneca ENHERTU improves PFS in Phase III
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said ENHERTU significantly improved progression-free survival versus standard first-line treatment in the Phase III DESTINY-Lung04 lung cancer trial.
Health
IM Cannabis sells IMC Holdings clearing C$9.4 million
IM Cannabis (NASDAQ:IMCC) executed a definitive agreement on August 16, 2026, to sell all shares of I.M.C. Holdings to Slil.com Holding to clear up to C$9.4 million in liabilities.
Health
Zai Lab, argenx report 15.4-point ALKIVIA improvement
Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.
Health
Centene reaffirms $4.80 EPS as CFO changes
Centene (NYSE:CNC) named Chris Neczypor as its next CFO from January 1, 2027, while reaffirming 2026 adjusted diluted EPS guidance above $4.80.
Health
HUTCHMED 338-patient trial improves survival outcomes
HUTCHMED (NASDAQ:HCM) reported that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival versus platinum-based chemotherapy in its 338-patient Phase 3 SAFFRON trial.
Health
Mesoblast completes 350-patient Phase 3 treatment
Mesoblast (NASDAQ:MESO) completed treatment of 350 patients in its pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain caused by degenerative disc disease.
Health
argenx reports 15.4-point gain in ALKIVIA trial
argenx (NASDAQ:ARGX) reported that subcutaneous VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint, producing a 15.4-point greater mean Total Improvement Score than placebo at Week 52.
Health
AstraZeneca, Daiichi Sankyo report phase 3 Enhertu results
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said Enhertu significantly improved progression-free survival versus standard first-line treatment for advanced HER2-mutant non-small cell lung cancer.